First case of acute generalized exanthematous pustulosis caused by pitavastatin: possible pathogenetic role of IL-36

2016 ◽  
Vol 26 (1) ◽  
pp. 106-107 ◽  
Author(s):  
Natsuko Saito-Sasaki ◽  
Yu Sawada ◽  
Shun Ohmori ◽  
Daisuke Omoto ◽  
Sanehito Haruyama ◽  
...  
Keyword(s):  
Pathogenetic Role ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Exanthematous Pustulosis

scholarly journals LB1568 Role of IL-36 in acute generalized exanthematous pustulosis

2018 ◽  
Vol 138 (9) ◽  
pp. B17
Author(s):  
B. Meier ◽  
M. Mellett ◽  
L. Feldmeyer ◽  
D. Jankovic ◽  
A. Navarini ◽  
...  
Keyword(s):  
Acute Generalized Exanthematous Pustulosis ◽  
Exanthematous Pustulosis

scholarly journals Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients

2022 ◽  
Vol 11 (2) ◽  
pp. 397
Author(s):  
Enriqueta Vallejo-Yagüe ◽  
Adrian Martinez-De la Torre ◽  
Omar S. Mohamad ◽  
Shweta Sabu ◽  
Andrea M. Burden
Keyword(s):  
Case Reports ◽  
Fatal Outcome ◽  
Case Series ◽  
Beta Lactam ◽  
Clinical Prognosis ◽  
Systemic Involvement ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Exanthematous Pustulosis ◽  
Time To Onset

Acute generalized exanthematous pustulosis (AGEP) is a rare skin reaction, commonly caused by drugs. Available evidence mostly relies on small studies or case reports. We collected published AGEP case reports and, subsequently, described the patient characteristics, suspect and concomitant drugs, time to onset, disease management, and clinical prognosis. This study included 297 AGEP patients (64.3% women) obtained from 250 published case reports or case series with individual patient data. AGEP affected patients of all ages, but the majority of patients (88.2%) were ≥25 years old. The most frequently reported suspect drugs were anti-infectives for systemic use (36.5%), particularly antibacterials for systemic use (31.0%), and especially beta-lactam antibacterials (18.3%) and macrolides (4.3%). Other frequent suspect drugs were antineoplastics (12.2%), and anti-inflammatory/anti-rheumatic products (5.2%) plus hydroxychloroquine (12.8%). Mean time to onset was 9.1 days (standard deviation SD 13.94). Some patients developed fever (64.3%) and systemic involvement (18.9%), and most patients (76.4%) received pharmacological treatment for AGEP. Seven patients died, although five of them were already critically ill prior to AGEP. In conclusion, antibiotics remain the most common suspected cause of AGEP. While case mortality rate may be up to 2.5%, disentangling the role of AGEP on the fatal outcome from the role of the preexisting health conditions remains challenging.

Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine: First Case Report in Canada and Review of the Literature

2013 ◽  
Vol 17 (6) ◽  
pp. 414-418 ◽  
Author(s):  
Kristy Bailey ◽  
Daniel Mckee ◽  
Judy Wismer ◽  
Neil Shear
Keyword(s):  
Adverse Reaction ◽  
Case Report ◽  
Drug Eruption ◽  
Spontaneous Resolution ◽  
Review Of The Literature ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Pathologic Findings ◽  
Complicated Course ◽  
Exanthematous Pustulosis

Background: Acute generalized exanthematous pustulosis (AGEP) is a rare drug eruption presenting with an acute, extensive formation of nonfollicular sterile pustules on an erythematous and edematous base. Typically, the rash is accompanied by fever and leukocytosis, with spontaneous resolution in < 15 days. The incidence of AGEP is estimated at one to five cases per million people per year. Only 18% of these are from nonantibiotics. Hydroxychloroquine (HCQ) is an antimalarial agent that is also used to treat various dermatologic and rheumatologic conditions. Objective: We report the first observation in Canada of a patient with AGEP induced by HCQ. Methods and Results: AGEP was diagnosed in a 48-year-old female who had been taking HCQ for 2 weeks and then developed a diffuse erythematous and edematous pustular eruption. Clinical and pathologic findings were consistent with a diagnosis of AGEP. The patient was treated with steroids and supportive measures. The rash resolved after 18 days and a complicated course in hospital. Conclusion: AGEP is a rare drug eruption, usually to antibiotics. We report the first case in Canada of AGEP as an adverse reaction to HCQ. Clinicians should keep in mind the possibility of this severe skin eruption.

Acute generalized exanthematous pustulosis due to allylisopropylacetylurea: role of IL-17-producing T cells

2011 ◽  
Vol 21 (1) ◽  
pp. 140-141 ◽  
Author(s):  
Takashi UEDA ◽  
Miho ABE ◽  
Ryouko OKIYAMA ◽  
Shuichi OYAMA ◽  
Kanji SATOH ◽  
...  
Keyword(s):  
T Cells ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Exanthematous Pustulosis

First case report of acute generalized exanthematous pustulosis (AGEP) caused by mifepristone

2019 ◽  
Vol 82 (3) ◽  
pp. 177-179 ◽  
Author(s):  
Li Zhang ◽  
Miaohong Qian ◽  
Ling Hong ◽  
Qunxiong Wu
Keyword(s):  
Case Report ◽  
Acute Generalized Exanthematous Pustulosis ◽  
First Case ◽  
Exanthematous Pustulosis
Sign in / Sign up

Export Citation Format

Share Document